Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3711-3714

  Karayannopoulou, Georgia ^a   Euvrard, Sylvie ^b   Kanitakis, Jean ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Basal cell carcinoma; Everolimus; Immunohistochemistry; Immunosuppression; MTOR; Organ transplantation; Phospho mTOR; Sirolimus; Skin; Squamous cell carcinoma

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

BASAL CELL CARCINOMA; EVEROLIMUS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSION; MTOR; ORGAN TRANSPLANTATION; PHOSPHO-MTOR; SIROLIMUS; SKIN; SQUAMOUS CELL CARCINOMA;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; SIROLIMUS; SKIN NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84885000565     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Wullschleger S, Loewith R and Hall MN: TOR signalling in growth and metabolism. Cell 124: 471-484, 2006.
2. Fingar D and Blenis J: Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171, 2004.
3. Chiang GG and Abraham RT: Targeting the mTOR signaling network in cancer. Trends Mol Med 13: 433-442, 2007.
4. Faivre S, Kroemer C and Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Disc 5: 671-688, 2006.
5. Pópulo H, Lopes JM and Soares P: The mTOR signalling pathway in human cancer. Int J Mol Sci 13: 1886-1918, 2012.
6. Schmacher G, Oidtmann M, Rosewicz S, Langrehr J, Jonas S, Mueller AR, Rueggeberg A, Neuhaus R, Bahra M, Jacob D, Gerlach H and Neuhaus P: Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which provokes cell growth. Transplant Proc 34: 1392-1393, 2002.
7. Guba M, von Breitenbuch P, Steinbauer P and Geissler E: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 8: 128-135, 2002.
8. Rival-Tringali AL, Euvrard S, Decullier E, Claudy A, Faure M and Kanitakis J: Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of human posttransplant cutaneous squamous cell carcinomas. Anticancer Res 29: 1927-1932, 2009.
9. Alvarado Y, Mita M, Vemulapalli S, Mahalingam D and Mita AC: Clinical activity of mammalian target of rapamycin inhibitors in solid tumors. Target Oncol 6: 69-94, 2011.
10. Malaguti P, Vari S, Cognetti F and Fabi A: The mammalian target of rapamycin inhibitors in breast cancer: Current evidence and future directions. Anticancer Res 33: 21-28, 2013.
11. Geissler EK: Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients? Transplant Proc 42 (9 Suppl): S32-35, 2010.
12. Monaco A: The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 87: 157-163, 2009.
13. Marsland A and Griffiths CE: The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 12: 618-622, 2002.
14. Koehl G, Andrassy J, Guba M, Richter S, Kroemer A, Scherer M, Seinbauer M, Graeb C, Schitt H, Jausch K and Geissler E: Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77: 1319-1326, 2004.
15. Mathew T, Kreis H and Friend P: Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Result from five multicentre studies. Clin Transplant 18: 446-449, 2004.
16. Kauffman H, Cherikh W, Cheng Y, Hanto DW and Kahan BD: Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80: 883-889, 2005.
17. Kahan BD, Yakupoglu YK, Schoenberg L, Knight RJ, Katz SM, Lai D and Van Buren CT : Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 80: 749-758, 2005.
18. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA and Neylan JF: Sirolimus therapy after early cyclosporin withdrawal reduces the risk for cancer of adult renal transplantation. J Am Soc Nephrol 17: 581-589, 2006.
19. Tessmer CS, Magalhães LV, Keitel E, Valar C, Gnatta D, Pra RL, Silveira FR, Dos Santos AF, Goldani JC, Garcia VD and Garcia CD: Conversion to sirolimus in renal transplant recipients with skin cancer. Transplantation 82: 1792-1793, 2006.
20. Fernández A, Marcén R, Pascual J, Galeano C, Ocaña J, Arellano EM, Alfaro C, Villafruela JJ, Burgos FJ and Ortuño J: Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. Transplant Proc 38: 2453-2455, 2006.
21. Pascual J, Fernández AM, Marcén R and Ortuño J: Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia-a case report. Nephrol Dial Transplant 21(Suppl 3:iii3): 8-41, 2006.
22. de Fijter JW. Use of proliferation signal inhibitors in nonmelanoma skin cancer following renal transplantation. Nephrol Dial Transplant 22(Suppl 1): i23-26, 2007.
23. Salgo R, Gossmann J, Schöfer H, Kachel HG, Kuck J, Geiger H, Kaufmann R and Scheuermann EH: Switch to a sirolimusbased immunosuppression in long-term renal transplant recipients: Reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 10: 1385-1393, 2010.
24. Euvrard S, Boissonnat P, Roussoullières A, Kanitakis J, Decullier E, Claudy and Sebbag L: Effect of everolimus conversion on skin cancers in calcineurin-inhibitor treated heart transplant recipients. Transpl Int 23: 855-857, 2010.
25. Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, Neylan JF, Korth-Bradley J, Goldberg-Alberts R, Maller ES, Sirolimus CONVERT Trial Study Group: Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-Month results from the CONVERT trial. Transplantation 92: 303-310, 2011.
26. Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders E, Del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra A, Hofbauer G, Pouteil-Noble C, Kanitakis J, Roux A, Decullier A and Dantal J on behalf of the TUMORAPA study group: Sirolimus and secondary skin cancer prevention in kidney transplant. N Engl J Med 367: 329-339, 2012.
27. Campbell S, Walker R, See Tai S, Jiang Q and Russ G. Randomized controlled trial o sirolimus for renal transplanrt recipients at high risk for nonmelanoma skin cancer. Am J Transplant 12: 1146-1156, 2012.
28. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, Aviel-Ronen S, Tsao MS, Hedley D and Siu L. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95: 1148-1154, 2006.
29. Chen SJ, Nakahara T, Takahara M, Kido M, Dugu L, Uchi H, Takeuchi S, Tu YT, Moroi Y and Furue M: Activation of the mammalian target of rapamycin signalling pathway in epidermal tumours and its correlation with cyclin-dependent kinase 2. Br J Dermatol 160: 442-445, 2009.
30. Campistol JM, Gutiérrez-Dalmau A, Revuelta I, Ferrer B, Mascaró JM Jr., Oppenheimer F and Albanell J: Distinct immunohistochemical phenotype of nonmelanoma skin cancers between renal transplant and immunocompetent populations. Transplantation 90: 986-992, 2010.
31. Euvrard S, Kanitakis J and Claudy A: Skin cancers after organ transplantation. N Engl J Med 348: 1681-1691, 2003.